Cargando…

CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease

Detalles Bibliográficos
Autores principales:	Wang, Yinhan, Xu, Haifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432308/ https://www.ncbi.nlm.nih.gov/pubmed/37600998 http://dx.doi.org/10.21037/hbsn-23-247

Ejemplares similares

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases
por: Han, Dong Wook, et al.
Publicado: (2023)

Challenges in the hepatic histopathology in non-alcoholic fatty liver disease
por: Brunt, Elizabeth M, et al.
Publicado: (2017)

A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?
por: Betzel, Bark, et al.
Publicado: (2014)

Practice guidance documents for the diagnosis and management of non-alcoholic fatty liver disease—recent updates and open questions
por: Lauschke, Volker M.
Publicado: (2023)

CRISPR/Cas9 or prime editing? – It depends on…
por: Schenke, Dirk
Publicado: (2020)

Genome editing before CRISPR: The gnostic bible
por: Kmiec, Eric B.
Publicado: (2023)

Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
por: Kasper, Philipp, et al.
Publicado: (2023)

3-D retina organoids: Building platforms for therapies of the future
por: Mazerik, Jessica N, et al.
Publicado: (2018)

Pediatric non alcoholic fatty liver disease: more on novel treatment targets
por: Vajro, Pietro, et al.
Publicado: (2013)

Oncogene-inducible organoids as a miniature platform to assess cancer characteristics
por: Mizutani, Tomohiro, et al.
Publicado: (2017)

Optimization of genome editing through CRISPR-Cas9 engineering
por: Zhang, Jian-Hua, et al.
Publicado: (2016)

CRISPR-Cas systems: ushering in the new genome editing era
por: Perez Rojo, Fernando, et al.
Publicado: (2018)

CRISPR-mediated gene editing to rescue haploinsufficient obesity syndrome
por: Wang, Zhifeng, et al.
Publicado: (2019)

Are the polyol pathway and hyperuricemia partners in the development of non‐alcoholic fatty liver disease in diabetes?
por: Hotta, Nigishi, et al.
Publicado: (2020)

Cancer surveillance in non-alcoholic fatty liver disease: A potential role for lipidomics
por: Best, Jan, et al.
Publicado: (2021)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

Organoid and microfluidics-based platforms for drug screening in COVID-19
por: Ramezankhani, Roya, et al.
Publicado: (2022)

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
por: Basheer, Maamon, et al.
Publicado: (2023)

Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies?
por: Ben-David, Uri
Publicado: (2013)

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
por: Song, Byeong Geun, et al.
Publicado: (2023)

The growing burden of non-alcoholic fatty liver disease on mortality
por: Cho, Ju-Yeon, et al.
Publicado: (2023)

Optimal diagnosis and management of non-alcoholic fatty liver disease
Publicado: (2022)

Gene editing using CRISPR/Cas9: implications for dual-use and biosecurity
por: DiEuliis, Diane, et al.
Publicado: (2017)

Commentary: CRISPR gene editing for inherited retinal dystrophies: Towards clinical translation
por: Bansal, Mayank, et al.
Publicado: (2022)

Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids
por: Schuster, Brooke, et al.
Publicado: (2020)

Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids
por: Geurts, Maarten H, et al.
Publicado: (2021)

Efficient genetic editing of human intestinal organoids using ribonucleoprotein-based CRISPR
por: Skoufou-Papoutsaki, Nefeli, et al.
Publicado: (2023)

Emerging liver organoid platforms and technologies
por: Lam, Do Thuy Uyen Ha, et al.
Publicado: (2021)

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
por: Chuah, Kee-Huat, et al.
Publicado: (2023)

Expanding CRISPR repertoire using CjCas9 as a smaller editing tool
por: Francis, Christopher, et al.
Publicado: (2022)

Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
por: Jung, Han Na, et al.
Publicado: (2023)

Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing?
por: Sanyal, Arun J.
Publicado: (2018)

Assessing the disease burden of non-alcoholic fatty liver disease in the real world – big data and big numbers
por: Schattenberg, Jörn M., et al.
Publicado: (2019)

Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
por: Eshraghian, Ahad
Publicado: (2017)

Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Schattenberg, Jörn M., et al.
Publicado: (2019)

Managing non‐alcoholic fatty liver disease in diabetes: Challenges and opportunities
por: Lee, Chi‐Ho, et al.
Publicado: (2016)

An analysis of polygenic risk scores for non-alcoholic fatty liver disease
por: Jun, Dae Won
Publicado: (2021)

Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease
por: O'Brien, Alastair
Publicado: (2022)

Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease
por: Han, Eugene
Publicado: (2022)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Alnimer, Lynna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_irr4299o274nermrkcai59qjmf